/ Media / News Features

Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals

July 1st, 2014

On July 1, 2014, Genentech entered into an agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California. Upon closing of this acquisition, Genentech will obtain rights to Seragon’s portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs), for the potential treatment of hormone receptor-positive breast cancer.

Read the press release


More than 150,000 women in the United States are diagnosed each year with hormone receptor-positive cancer, which hijacks hormones like estrogen to fuel the growth of cancer cells.

These investigational next-generation SERDs will

  • complement Genentech’s existing research and development programs in breast cancer
  • provide an opportunity for Genentech to continue our 30 plus year commitment to breast cancer research
  • strengthen Genentech’s oncology pipeline 

Supporting Information


Trashing a Common Cancer Driver

Investigational next-generation selective estrogen receptor degraders (SERDs) are a class of small molecules that may exert a big effect on a key driver of breast cancer.

Drug Development: It Takes an Ecosystem

Public research, private backing and companies like Genentech are all aspects of a life science "ecosystem" that work together, keeping the best science moving forward.

New Insights on Breast Cancer Research

With the recent acquisition of Seragon, Genentech is excited to add a new class of investigational medicines known as SERDs to our pipeline.